Misoprostol prior to inserting an intrauterine device in nulligravidas: A randomized clinical trial

Human Reproduction

Volumn 28, Issue 8, 2013, Pages 2118-2125

  Scavuzzi, Adriana ^a   Souza, Alex S R ^a   Costa, Aurélio A R ^a,b   Amorim, Melania M R ^a,c  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^b Faculdade Pernambucana de Saude FPS   (Brazil)

^c FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

Author keywords

contraception; intrauterine devices; misoprostol; nulligravidas

Indexed keywords

MISOPROSTOL; PLACEBO;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FAINTNESS; FEMALE; HUMAN; HYPERTHERMIA; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE DEVICE EXPULSION; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; METRORRHAGIA; MUSCLE CRAMP; NAUSEA; NULLIGRAVIDA; PELVIC INFLAMMATORY DISEASE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPOTTING; THERAPY EFFECT; UTERINE CERVIX DILATATION; VAGINA PAIN; VISUAL ANALOG SCALE; VOMITING;

EID: 84880523267     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det240     Document Type: Article

References (25)

1. Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009:CD007373.
2. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol 2007;110:1493-1495.
3. Arias F. Pharmacology of oxytocin and prostaglandins. Clin Obstet Gynecol 2000;43:455-468.
4. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004;19:81-84. (Pubitemid 38072011)
5. Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 2011;84:e11-16.
6. d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 2007;75(6 Suppl.):S2-S7.
7. Dijkhuizen K, Dekkers OM, Holleboom CA, de Groot CJ, Hellebrekers BW, van Roosmalen GJ, Janssen CA, Helmerhorst FM. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011; 26:323-329.
8. Edelman AB, Schaefer E, Olson A, Van Houten L, Bednarek P, Leclair C, Jensen JT. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception 2011; 84:234-239.
9. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987.
10. Fiala C, Gemzell-Danielsson K, Tang OS, von Hertzen H. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynecol Obstet 2007;99 (Suppl. 2):S168-S171. (Pubitemid 350110439)
11. Forthofer KV. A clinical review of the intrauterine device as an effective method of contraception. J Obstet Gynecol Neonatal Nurs 2009; 38:693-698.
12. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2001:CD001327.
13. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol 2004;190:55-59. (Pubitemid 38156323)
14. Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, Hurskainen R, Gemzell-Danielsson K. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception 2010;81:481-486.
15. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001; 345:561-567. (Pubitemid 32772097)
16. Li YT, Kuo TC, Kuan LC, Chu YC. Cervical softening with vaginal misoprostol before intrauterine device insertion. Int J Gynaecol Obstet 2005;89:67-68. (Pubitemid 40381151)
17. Morgan KW. The intrauterine device: rethinking old paradigms. J Midwifery Womens Health 2006;51:464-470. (Pubitemid 44615966)
18. Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007;22:2647-2652. (Pubitemid 47434207)
19. Scavuzzi A, Amorim M, Acioly D, Costa A, Melo N, Araújo T, Souza A, Chacon B. Misoprostol prior to insertion of intrauterine device in nulligravida: a randomized controlled trial. A pilot study. Int J Gynaecol Obstet 2009;107(2 Suppl.):S330.
20. Schaefer E, Van Houten L, Olson A, Leclair C, Bednarek PH, Edelman A. Prophylactic misoprostol prior to IUD insertion in nulliparous women. Contraception 2010;82:188.
21. Stanback J, Shelton JD. Pelvic inflammatory disease attributable to the IUD: modeling risk in West Africa. Contraception 2008;77:227-229.
22. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332-336. (Pubitemid 34168436)
23. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007; 99(Suppl. 2):S160-S167. (Pubitemid 350101541)
24. Ward K, Jacobson JC, Turok DK, Murphy PA. A survey of provider experience with misoprostol to facilitate intrauterine device insertion in nulliparous women. Contraception 2011;84:594-599.
25. World Health Organization (WHO). Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Initiating and Continuing Use of Contraceptive Methods, 3rd edn. Geneva, Switzerland: WHO, 2004, 17.